(Total Views: 405)
Posted On: 04/06/2020 9:19:32 AM
Post# of 154032
my breakdown of this press release
Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated
7-day results for the first 10 patients will be available this week
7-day results from the first four patients are available and are very promising
first two COVID-19 patients have been treated with leronlimab under the Company’s Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications.
The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.
CytoDyn also anticipates initiating its other COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients
Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, “We are encouraged by the positive results demonstrated with leronlimab in the New York patients. Our team is working hard to distribute leronlimab to multiple clinical sites to initiate therapy in patients with severe COVID-19 disease. While every patient is experiencing different comorbidities, we are seeing similar clinical responses, which we believe is a reflection of leronlimab’s mechanism of action.
Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated
7-day results for the first 10 patients will be available this week
7-day results from the first four patients are available and are very promising
first two COVID-19 patients have been treated with leronlimab under the Company’s Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications.
The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.
CytoDyn also anticipates initiating its other COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients
Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, “We are encouraged by the positive results demonstrated with leronlimab in the New York patients. Our team is working hard to distribute leronlimab to multiple clinical sites to initiate therapy in patients with severe COVID-19 disease. While every patient is experiencing different comorbidities, we are seeing similar clinical responses, which we believe is a reflection of leronlimab’s mechanism of action.
(2)
(0)
